Aspen Pharma (EU Excessive Pricing)

When patents expire on life-saving drugs, generics usually cut prices. But if only one supplier remains for a niche oncology product, hospitals may have no alternative—creating dominance out of scarcity.

Aspen acquired portfolios of classic cancer medicines and allegedly imposed sudden, massive price increases across Europe, sometimes multiplying prices several-fold overnight.

National health systems pushed back. According to the Commission, Aspen threatened to withdraw supplies from countries that would not accept the new price lists—using medicine access as leverage.

Italian and other national authorities investigated first, feeding EU-level scrutiny of whether this was lawful pricing or exploitative abuse by a dominant supplier.

The 2018 decision found Article 102 violations for excessive pricing combined with abusive threats. The fine was modest in euro terms but symbolically important for pharma enforcement.

Patients and hospitals faced budget shocks; doctors treated with essential drugs where monopoly power met moral outrage.

Aspen illustrates EU willingness to police exploitative pricing in concentrated generic niches—not only cartels and mergers.

Off-patent does not always mean competitive pricing.

Healthcare systems depend on antitrust when markets fail patients.

Dominance can arise from sole-supplier legacy drugs.

Aspen held dominant positions in specific oncology generics.

Price increases were excessive and unfair.

Supply threats coerced public payers.

Aspen cited manufacturing costs and low historical prices.

It argued commercial negotiation, not abuse, explained outcomes.

Drug budgets affect insurance premiums and tax-funded healthcare.

Hospitals should document supplier threats when prices spike.